Cargando…

Impact of SARS-CoV-2 Delta variant on incubation, transmission settings and vaccine effectiveness: Results from a nationwide case-control study in France

BACKGROUND: We aimed to assess the settings and activities associated with SARS-CoV-2 infection in the context of B.1.617.2 (Delta) variant circulation in France, as well as the protection against symptomatic Delta infection. METHODS: In this nationwide case-control study, cases were SARS-CoV-2 infe...

Descripción completa

Detalles Bibliográficos
Autores principales: Grant, Rebecca, Charmet, Tiffany, Schaeffer, Laura, Galmiche, Simon, Madec, Yoann, Von Platen, Cassandre, Chény, Olivia, Omar, Faïza, David, Christophe, Rogoff, Alexandra, Paireau, Juliette, Cauchemez, Simon, Carrat, Fabrice, Septfons, Alexandra, Levy-Bruhl, Daniel, Mailles, Alexandra, Fontanet, Arnaud
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8616730/
https://www.ncbi.nlm.nih.gov/pubmed/34849500
http://dx.doi.org/10.1016/j.lanepe.2021.100278
_version_ 1784604408209735680
author Grant, Rebecca
Charmet, Tiffany
Schaeffer, Laura
Galmiche, Simon
Madec, Yoann
Von Platen, Cassandre
Chény, Olivia
Omar, Faïza
David, Christophe
Rogoff, Alexandra
Paireau, Juliette
Cauchemez, Simon
Carrat, Fabrice
Septfons, Alexandra
Levy-Bruhl, Daniel
Mailles, Alexandra
Fontanet, Arnaud
author_facet Grant, Rebecca
Charmet, Tiffany
Schaeffer, Laura
Galmiche, Simon
Madec, Yoann
Von Platen, Cassandre
Chény, Olivia
Omar, Faïza
David, Christophe
Rogoff, Alexandra
Paireau, Juliette
Cauchemez, Simon
Carrat, Fabrice
Septfons, Alexandra
Levy-Bruhl, Daniel
Mailles, Alexandra
Fontanet, Arnaud
author_sort Grant, Rebecca
collection PubMed
description BACKGROUND: We aimed to assess the settings and activities associated with SARS-CoV-2 infection in the context of B.1.617.2 (Delta) variant circulation in France, as well as the protection against symptomatic Delta infection. METHODS: In this nationwide case-control study, cases were SARS-CoV-2 infected adults recruited between 23 May and 13 August 2021. Controls were non-infected adults from a national representative panel matched to cases by age, sex, region, population density and calendar week. Participants completed an online questionnaire and multivariable logistic regression analysis was used to determine the association between acute SARS-CoV-2 infection and recent activity-related exposures, past history of SARS-CoV-2 infection, and COVID-19 vaccination. FINDINGS: We did not find any differences in the settings and activities associated with Delta versus non-Delta infections and grouped them for subsequent analyses. In multivariable analysis involving 12634 cases (8644 Delta and 3990 non-Delta) and 5560 controls, we found individuals under 40 years and attending bars (aOR:1.9; 95%CI:1.6-2.2) or parties (aOR:3.4; 95%CI:2.8-4.2) to be at increased risk of infection. In those aged 40 years and older, having children attend daycare (aOR:1.9; 95%CI:1.1-3.3), kindergarten (aOR:1.6; 95%CI:1.2-2.1), primary school (aOR:1.4; 95%CI:1.2-1.6) or middle school (aOR:1.3; 95%CI:1.2-1.6) were associated with increased risk of infection. We found strong protection against symptomatic Delta infection for those with prior infection whether it was recent (2-6 months) (95%; 95%CI:90-97) or associated with one dose (85%; 95%CI:78-90) or two doses of mRNA vaccine (96%; 95%CI:87-99). For those without past infection, protection was lower with two doses of mRNA vaccine (67%; 95%CI:63-71). INTERPRETATION: In line with other observational studies, we find reduced vaccine effectiveness against symptomatic Delta infections. The settings and activities at increased risk of infection indicate where efforts to reinforce individual and public health measures need to be concentrated.
format Online
Article
Text
id pubmed-8616730
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-86167302021-11-26 Impact of SARS-CoV-2 Delta variant on incubation, transmission settings and vaccine effectiveness: Results from a nationwide case-control study in France Grant, Rebecca Charmet, Tiffany Schaeffer, Laura Galmiche, Simon Madec, Yoann Von Platen, Cassandre Chény, Olivia Omar, Faïza David, Christophe Rogoff, Alexandra Paireau, Juliette Cauchemez, Simon Carrat, Fabrice Septfons, Alexandra Levy-Bruhl, Daniel Mailles, Alexandra Fontanet, Arnaud Lancet Reg Health Eur Articles BACKGROUND: We aimed to assess the settings and activities associated with SARS-CoV-2 infection in the context of B.1.617.2 (Delta) variant circulation in France, as well as the protection against symptomatic Delta infection. METHODS: In this nationwide case-control study, cases were SARS-CoV-2 infected adults recruited between 23 May and 13 August 2021. Controls were non-infected adults from a national representative panel matched to cases by age, sex, region, population density and calendar week. Participants completed an online questionnaire and multivariable logistic regression analysis was used to determine the association between acute SARS-CoV-2 infection and recent activity-related exposures, past history of SARS-CoV-2 infection, and COVID-19 vaccination. FINDINGS: We did not find any differences in the settings and activities associated with Delta versus non-Delta infections and grouped them for subsequent analyses. In multivariable analysis involving 12634 cases (8644 Delta and 3990 non-Delta) and 5560 controls, we found individuals under 40 years and attending bars (aOR:1.9; 95%CI:1.6-2.2) or parties (aOR:3.4; 95%CI:2.8-4.2) to be at increased risk of infection. In those aged 40 years and older, having children attend daycare (aOR:1.9; 95%CI:1.1-3.3), kindergarten (aOR:1.6; 95%CI:1.2-2.1), primary school (aOR:1.4; 95%CI:1.2-1.6) or middle school (aOR:1.3; 95%CI:1.2-1.6) were associated with increased risk of infection. We found strong protection against symptomatic Delta infection for those with prior infection whether it was recent (2-6 months) (95%; 95%CI:90-97) or associated with one dose (85%; 95%CI:78-90) or two doses of mRNA vaccine (96%; 95%CI:87-99). For those without past infection, protection was lower with two doses of mRNA vaccine (67%; 95%CI:63-71). INTERPRETATION: In line with other observational studies, we find reduced vaccine effectiveness against symptomatic Delta infections. The settings and activities at increased risk of infection indicate where efforts to reinforce individual and public health measures need to be concentrated. Elsevier 2021-11-26 /pmc/articles/PMC8616730/ /pubmed/34849500 http://dx.doi.org/10.1016/j.lanepe.2021.100278 Text en © 2021 The Author(s) https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Articles
Grant, Rebecca
Charmet, Tiffany
Schaeffer, Laura
Galmiche, Simon
Madec, Yoann
Von Platen, Cassandre
Chény, Olivia
Omar, Faïza
David, Christophe
Rogoff, Alexandra
Paireau, Juliette
Cauchemez, Simon
Carrat, Fabrice
Septfons, Alexandra
Levy-Bruhl, Daniel
Mailles, Alexandra
Fontanet, Arnaud
Impact of SARS-CoV-2 Delta variant on incubation, transmission settings and vaccine effectiveness: Results from a nationwide case-control study in France
title Impact of SARS-CoV-2 Delta variant on incubation, transmission settings and vaccine effectiveness: Results from a nationwide case-control study in France
title_full Impact of SARS-CoV-2 Delta variant on incubation, transmission settings and vaccine effectiveness: Results from a nationwide case-control study in France
title_fullStr Impact of SARS-CoV-2 Delta variant on incubation, transmission settings and vaccine effectiveness: Results from a nationwide case-control study in France
title_full_unstemmed Impact of SARS-CoV-2 Delta variant on incubation, transmission settings and vaccine effectiveness: Results from a nationwide case-control study in France
title_short Impact of SARS-CoV-2 Delta variant on incubation, transmission settings and vaccine effectiveness: Results from a nationwide case-control study in France
title_sort impact of sars-cov-2 delta variant on incubation, transmission settings and vaccine effectiveness: results from a nationwide case-control study in france
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8616730/
https://www.ncbi.nlm.nih.gov/pubmed/34849500
http://dx.doi.org/10.1016/j.lanepe.2021.100278
work_keys_str_mv AT grantrebecca impactofsarscov2deltavariantonincubationtransmissionsettingsandvaccineeffectivenessresultsfromanationwidecasecontrolstudyinfrance
AT charmettiffany impactofsarscov2deltavariantonincubationtransmissionsettingsandvaccineeffectivenessresultsfromanationwidecasecontrolstudyinfrance
AT schaefferlaura impactofsarscov2deltavariantonincubationtransmissionsettingsandvaccineeffectivenessresultsfromanationwidecasecontrolstudyinfrance
AT galmichesimon impactofsarscov2deltavariantonincubationtransmissionsettingsandvaccineeffectivenessresultsfromanationwidecasecontrolstudyinfrance
AT madecyoann impactofsarscov2deltavariantonincubationtransmissionsettingsandvaccineeffectivenessresultsfromanationwidecasecontrolstudyinfrance
AT vonplatencassandre impactofsarscov2deltavariantonincubationtransmissionsettingsandvaccineeffectivenessresultsfromanationwidecasecontrolstudyinfrance
AT chenyolivia impactofsarscov2deltavariantonincubationtransmissionsettingsandvaccineeffectivenessresultsfromanationwidecasecontrolstudyinfrance
AT omarfaiza impactofsarscov2deltavariantonincubationtransmissionsettingsandvaccineeffectivenessresultsfromanationwidecasecontrolstudyinfrance
AT davidchristophe impactofsarscov2deltavariantonincubationtransmissionsettingsandvaccineeffectivenessresultsfromanationwidecasecontrolstudyinfrance
AT rogoffalexandra impactofsarscov2deltavariantonincubationtransmissionsettingsandvaccineeffectivenessresultsfromanationwidecasecontrolstudyinfrance
AT paireaujuliette impactofsarscov2deltavariantonincubationtransmissionsettingsandvaccineeffectivenessresultsfromanationwidecasecontrolstudyinfrance
AT cauchemezsimon impactofsarscov2deltavariantonincubationtransmissionsettingsandvaccineeffectivenessresultsfromanationwidecasecontrolstudyinfrance
AT carratfabrice impactofsarscov2deltavariantonincubationtransmissionsettingsandvaccineeffectivenessresultsfromanationwidecasecontrolstudyinfrance
AT septfonsalexandra impactofsarscov2deltavariantonincubationtransmissionsettingsandvaccineeffectivenessresultsfromanationwidecasecontrolstudyinfrance
AT levybruhldaniel impactofsarscov2deltavariantonincubationtransmissionsettingsandvaccineeffectivenessresultsfromanationwidecasecontrolstudyinfrance
AT maillesalexandra impactofsarscov2deltavariantonincubationtransmissionsettingsandvaccineeffectivenessresultsfromanationwidecasecontrolstudyinfrance
AT fontanetarnaud impactofsarscov2deltavariantonincubationtransmissionsettingsandvaccineeffectivenessresultsfromanationwidecasecontrolstudyinfrance